Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs. We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP-4 inhibitor, alogliptin. Our case suggests that there is a difference in the risk of angioedema among DPP-4 inhibitors. To clarify this possibility, further investigation on the risk of angioedema among DPP-4 inhibitors is warranted.

Original languageEnglish
JournalDiabetic medicine : a journal of the British Diabetic Association
Volume30
Issue number4
DOIs
Publication statusPublished - 2013 Apr

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Angioedema
Drug-Related Side Effects and Adverse Reactions

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{bfcb5be6acc3477f904371bcf006f0cb,
title = "Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?",
abstract = "Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs. We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP-4 inhibitor, alogliptin. Our case suggests that there is a difference in the risk of angioedema among DPP-4 inhibitors. To clarify this possibility, further investigation on the risk of angioedema among DPP-4 inhibitors is warranted.",
author = "Yoshifumi Saisho and Hiroshi Itoh",
year = "2013",
month = "4",
doi = "10.1111/dme.12134",
language = "English",
volume = "30",
journal = "Diabetic medicine : a journal of the British Diabetic Association",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Dipeptidyl peptidase-4 inhibitors and angioedema

T2 - a class effect?

AU - Saisho, Yoshifumi

AU - Itoh, Hiroshi

PY - 2013/4

Y1 - 2013/4

N2 - Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs. We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP-4 inhibitor, alogliptin. Our case suggests that there is a difference in the risk of angioedema among DPP-4 inhibitors. To clarify this possibility, further investigation on the risk of angioedema among DPP-4 inhibitors is warranted.

AB - Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs. We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP-4 inhibitor, alogliptin. Our case suggests that there is a difference in the risk of angioedema among DPP-4 inhibitors. To clarify this possibility, further investigation on the risk of angioedema among DPP-4 inhibitors is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84883501384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883501384&partnerID=8YFLogxK

U2 - 10.1111/dme.12134

DO - 10.1111/dme.12134

M3 - Article

C2 - 23323612

AN - SCOPUS:84883501384

VL - 30

JO - Diabetic medicine : a journal of the British Diabetic Association

JF - Diabetic medicine : a journal of the British Diabetic Association

SN - 0742-3071

IS - 4

ER -